JP2012516889A - 微生物因子の増殖及び生存能力を低下させる方法 - Google Patents

微生物因子の増殖及び生存能力を低下させる方法 Download PDF

Info

Publication number
JP2012516889A
JP2012516889A JP2011549138A JP2011549138A JP2012516889A JP 2012516889 A JP2012516889 A JP 2012516889A JP 2011549138 A JP2011549138 A JP 2011549138A JP 2011549138 A JP2011549138 A JP 2011549138A JP 2012516889 A JP2012516889 A JP 2012516889A
Authority
JP
Japan
Prior art keywords
surfactant
formulation
agent
antimicrobial agent
trichophyton
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011549138A
Other languages
English (en)
Japanese (ja)
Inventor
ヘンリー,ウィリアム
クルーン,アンク−アンドレ
サマートン,リンダ
Original Assignee
ターゲッティド デリバリー テクノロジーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41460484&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012516889(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ターゲッティド デリバリー テクノロジーズ リミテッド filed Critical ターゲッティド デリバリー テクノロジーズ リミテッド
Publication of JP2012516889A publication Critical patent/JP2012516889A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2011549138A 2009-02-05 2009-07-23 微生物因子の増殖及び生存能力を低下させる方法 Withdrawn JP2012516889A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15028809P 2009-02-05 2009-02-05
US61/150,288 2009-02-05
PCT/US2009/051593 WO2010090654A1 (en) 2009-02-05 2009-07-23 Methods of reducing the proliferation and viability of microbial agents

Publications (1)

Publication Number Publication Date
JP2012516889A true JP2012516889A (ja) 2012-07-26

Family

ID=41460484

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011549138A Withdrawn JP2012516889A (ja) 2009-02-05 2009-07-23 微生物因子の増殖及び生存能力を低下させる方法

Country Status (19)

Country Link
US (2) US20100197621A1 (es)
EP (1) EP2393480A1 (es)
JP (1) JP2012516889A (es)
KR (1) KR20110128283A (es)
CN (1) CN102368998A (es)
AU (1) AU2009339445A1 (es)
BR (1) BRPI0924302A2 (es)
CA (1) CA2751412A1 (es)
CO (1) CO6410285A2 (es)
CR (1) CR20110409A (es)
EC (1) ECSP11011246A (es)
IL (1) IL214331A0 (es)
MX (1) MX2011008204A (es)
NI (1) NI201100152A (es)
PE (1) PE20120326A1 (es)
RU (1) RU2011136624A (es)
SG (1) SG173183A1 (es)
WO (1) WO2010090654A1 (es)
ZA (1) ZA201105758B (es)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015020951A (ja) * 2013-07-16 2015-02-02 株式会社ゲノム創薬研究所 抗菌活性促進剤及び該抗菌活性促進剤を含有する感染症治療薬
KR101749687B1 (ko) 2016-04-25 2017-06-21 경북대학교 산학협력단 7,10-에폭시옥타데카-7,9-다이에노산을 유효성분으로 포함하는 항균 조성물
KR101792239B1 (ko) 2016-11-01 2017-10-31 경북대학교 산학협력단 7,10-에폭시옥타데카-7,9-다이에노산 및 항생제를 유효성분으로 포함하는 항균 조성물
WO2017188692A1 (ko) * 2016-04-25 2017-11-02 경북대학교 산학협력단 7,10-에폭시옥타데카-7,9-다이에노산을 유효성분으로 포함하는 항균 조성물
JP2019108388A (ja) * 2013-10-03 2019-07-04 ダウ ファーマシューティカル サイエンシーズ,インコーポレイティド 安定化エフィナコナゾール組成物
US11654139B2 (en) 2013-11-22 2023-05-23 Bausch Health Ireland Limited Anti-infective methods, compositions, and devices

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
BR112012003834A2 (pt) * 2009-08-21 2017-08-08 Targeted Delivery Tech Limited métodos para tratamento de distúrbios e para tratamentos de deficiências em ácidos graxos, hipertrigliceridemia ou hipercolesterolemia e pacote
EP2571847B1 (en) 2010-05-19 2016-09-21 Sandoz AG Process for the preparation of chiral hydrazides
CA2798007C (en) 2010-05-19 2018-10-23 Sandoz Ag Preparation of posaconazole intermediates
AU2011254654B2 (en) 2010-05-19 2016-01-07 Sandoz Ag Process for the preparation of chiral triazolones
WO2011144657A1 (en) 2010-05-19 2011-11-24 Sandoz Ag Purification of posaconazole and posaconazole intermediates
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
CN103402543B (zh) * 2010-12-16 2015-09-16 德克萨斯州立大学董事会 用于胃肠外施用的吡咯药物制剂及其制备方法和治疗对吡咯化合物敏感的疾病的使用方法
CA3027870C (en) * 2011-03-15 2021-09-07 Thompson Cooper Laboratories, Llc Compositions and methods for treatment of infections
DE112012001386T5 (de) * 2011-03-21 2013-12-19 Gregor Cevc Optimierte Präparate von sehr anpassungsfähigen Aggregaten
JP6080312B2 (ja) 2011-04-28 2017-02-15 プラットフォーム ブライトワークス トゥー, リミテッド 親油性医薬用薬剤の改良された非経口製剤ならびにそれを調製および使用するための方法
WO2012172015A1 (en) 2011-06-16 2012-12-20 Sandoz Ag Process for the preparation of a chiral compound
WO2013043830A1 (en) * 2011-09-20 2013-03-28 Molecular Express, Inc. Nanoparticle formulations of poorly soluble compounds
KR101350442B1 (ko) * 2011-10-12 2014-01-15 김동진 클로르헥시딘을 함유하는 안정한 수용성 살균방부제 조성물
WO2013057208A1 (en) 2011-10-18 2013-04-25 Targeted Delivery Technologies Limited Compositions and methods for reducing the proliferation and viability of microbial agents
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
CN102659734B (zh) * 2012-04-28 2014-07-16 山东大学 一种三烯抗生素的制备方法
WO2013186320A1 (en) * 2012-06-14 2013-12-19 Sandoz Ag Pharmaceutical composition comprising crystalline posaconazole
WO2014062621A1 (en) * 2012-10-15 2014-04-24 Stc.Unm Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
US8815952B1 (en) * 2013-03-15 2014-08-26 Carnell & Herzog, LLC Chlorhexadine antiseptic
CN103690543B (zh) * 2013-12-24 2015-09-09 广西医科大学 杀死烟曲霉菌的组合物及方法
PL3316856T3 (pl) 2015-06-30 2021-10-25 Sequessome Technology Holdings Limited Zmieszane formulacje
CN106546668A (zh) * 2015-09-22 2017-03-29 陕西合成药业股份有限公司 一种分离福司氟康唑或其药用盐有关物质的hplc方法
CN106890167A (zh) * 2015-12-17 2017-06-27 中国科学院上海巴斯德研究所 一种具有抗结核活性的化合物及其应用
CN108472505A (zh) * 2015-12-22 2018-08-31 3M创新有限公司 用于孢子移除的方法
CN107184551B (zh) * 2017-06-09 2020-09-01 甘肃新天马制药股份有限公司 一种利拉萘酯双粒径分布乳剂及其制备方法
CN112791048B (zh) * 2020-12-31 2023-01-17 海南海神同洲制药有限公司 一种硝酸舍他康唑栓及其制备方法
CN112931213B (zh) * 2021-03-29 2022-05-27 东北林业大学 一种杨树外植体脱毒试剂、脱毒方法及应用
CN114432297B (zh) * 2022-02-07 2022-10-11 中国人民解放军军事科学院军事医学研究院 Zaragozic acid A在产气荚膜梭菌Epsilon毒素中毒救治中的应用
CN115644062B (zh) * 2022-11-03 2023-11-17 天津科润农业科技股份有限公司 一种提高难出胚大白菜胚诱导率的培养基及其方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6348214A (ja) * 1986-08-18 1988-02-29 Morishita Seiyaku Kk 1−〔2−(2,4−ジクロロフエニル)−3−メチル−1−ペンテニル〕−1h−イミダゾ−ルを含有する水中油型脂肪乳剤
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
GB9111611D0 (en) * 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
DE4336434A1 (de) * 1993-10-26 1995-04-27 Hoechst Ag Pharmazeutische Zubereitung für die parenterale, enterale und dermale Verabreichung von praktisch unlöslichen Arzneistoffen und Verfahren zu ihrer Herstellung
ES2172795T3 (es) * 1996-06-07 2002-10-01 Dsm Nv Nuevos fungicidas enzimaticos.
EP0872229A1 (en) * 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a phospholipid
AU764001B2 (en) * 1998-05-29 2003-08-07 Skyepharma Canada Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
US20030215493A1 (en) * 2002-04-30 2003-11-20 Patel Pravin M. Composition and method for dermatological treatment
US6846837B2 (en) * 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
WO2006029074A2 (en) * 2004-09-03 2006-03-16 Piedmont Pharmaceuticals, Llc Methods for transmembrane treatment and prevention of otitis media
US8633191B2 (en) * 2004-09-21 2014-01-21 Stephen C. Perry Anti-microbial and anti-fungal shampoo for mammals especially humans and dogs
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060222716A1 (en) * 2005-04-01 2006-10-05 Joseph Schwarz Colloidal solid lipid vehicle for pharmaceutical use
CN101273971A (zh) * 2008-05-09 2008-10-01 绍兴文理学院 抗真菌药物的醇质体制剂及其制备方法
WO2010010470A2 (en) * 2008-07-23 2010-01-28 Tdt, Ltd Methods of administering topical antifungal formulations for the treatment of fungal infections

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015020951A (ja) * 2013-07-16 2015-02-02 株式会社ゲノム創薬研究所 抗菌活性促進剤及び該抗菌活性促進剤を含有する感染症治療薬
JP2019108388A (ja) * 2013-10-03 2019-07-04 ダウ ファーマシューティカル サイエンシーズ,インコーポレイティド 安定化エフィナコナゾール組成物
US10864274B2 (en) 2013-10-03 2020-12-15 Bausch Health Ireland Limited Stabilized efinaconazole formulations
US11654139B2 (en) 2013-11-22 2023-05-23 Bausch Health Ireland Limited Anti-infective methods, compositions, and devices
KR101749687B1 (ko) 2016-04-25 2017-06-21 경북대학교 산학협력단 7,10-에폭시옥타데카-7,9-다이에노산을 유효성분으로 포함하는 항균 조성물
WO2017188692A1 (ko) * 2016-04-25 2017-11-02 경북대학교 산학협력단 7,10-에폭시옥타데카-7,9-다이에노산을 유효성분으로 포함하는 항균 조성물
US10695314B2 (en) 2016-04-25 2020-06-30 Kyungpook National University Industry-Academic Cooperation Foundation Antimicrobial composition containing 7,10-epoxyoctadeca-7,9-dienoic acid as active ingredient
KR101792239B1 (ko) 2016-11-01 2017-10-31 경북대학교 산학협력단 7,10-에폭시옥타데카-7,9-다이에노산 및 항생제를 유효성분으로 포함하는 항균 조성물

Also Published As

Publication number Publication date
RU2011136624A (ru) 2013-03-10
CA2751412A1 (en) 2010-08-12
NI201100152A (es) 2012-03-28
KR20110128283A (ko) 2011-11-29
IL214331A0 (en) 2011-09-27
EP2393480A1 (en) 2011-12-14
SG173183A1 (en) 2011-09-29
AU2009339445A1 (en) 2011-08-18
BRPI0924302A2 (pt) 2019-09-24
US20120245107A1 (en) 2012-09-27
US20100197621A1 (en) 2010-08-05
CN102368998A (zh) 2012-03-07
PE20120326A1 (es) 2012-04-20
CO6410285A2 (es) 2012-03-30
ZA201105758B (en) 2013-01-30
MX2011008204A (es) 2011-12-06
CR20110409A (es) 2011-11-02
ECSP11011246A (es) 2011-11-30
WO2010090654A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
JP2012516889A (ja) 微生物因子の増殖及び生存能力を低下させる方法
US7820720B2 (en) Topical terbinafine formulations and methods of administering same for the treatment of fungal infections
US9333190B2 (en) Endoxifen compositions and methods
AU2010255391B2 (en) Formulations for the treatment of deep tissue pain
KR20120129864A (ko) 소포성 제형
CN106132970B (zh) 硼酸酯和其药物制剂
JP2021091730A (ja) 多相組成物
EA039626B1 (ru) Применение везикулярной композиции для лечения сниженной подвижности сустава
WO2014078801A1 (en) Methods and compositions comprising guanidines for treating biofilms
Altube et al. Fast biofilm penetration and anti-PAO1 activity of nebulized azithromycin in nanoarchaeosomes
WO2013057208A1 (en) Compositions and methods for reducing the proliferation and viability of microbial agents
JP2015511618A (ja) 小胞製剤
US20230390316A1 (en) Antimicrobial compositions and methods of use
JP2015516454A (ja) ベシクル製剤のキットおよび使用
JP2015516453A (ja) ベシクル製剤の使用および方法
JPWO2017222042A1 (ja) 眼用医薬組成物
WO2024017254A1 (zh) 氨基脂质化合物、其制备方法和应用
RU2783649C2 (ru) Жидкая фармацевтическая композиция нафтифина
US20140017301A1 (en) Drug-free compositions and methods for diminishing peripheral inflammation and pain
CN107811969B (zh) 一种高稳定性的非囊泡型纳米颗粒及其在治疗真菌感染中的应用
WO2012020790A1 (ja) 感染症治療薬
Ghosh Interaction of Cationic and Anionic Surfactants: Preparation of pH-Responsive Stable Vesicles for Drug Delivery Applications
AU2015202217A1 (en) Vesicular formulations

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20121002